BRAF and cancer: In our study, one deactivating BRAFG466V mutation was paired with an oncogenic KRASG12S mutation, and one deactivating BRAFG469E mutation was paired with an oncogenic RAF1S257L alteration, supporting the notion of an evolutionary adaptation in the cancer genome to overcome BRAF mutations with impaired function.